Rubicon Research Ltd

Rubicon Research announced that the 27th Annual General Meeting(AGM) of the company will be held on 26 August 2026.

The board of Rubicon Research at its meeting held on 20 July 2026 has approved the scheme of merger of for Kia Health Tech, a wholly owned subsidiary, (Transferor Company) with the company.

Rubicon Research has fixed 07 August 2026 as record date for payment of final dividend for FY 2026.

Rubicon Research has allotted 1,49,158 equity shares under ESOS on 20 July 2026. Consequently, the issued, subscribed and paid-up equity share capital of the Company stands increased to Rs 16,55,31,908 comprising of 16,55,31,908 equity shares of face value Re 1 each.

The inspection was carried out from 29 June to 3 July 2026 and marked the first US FDA review of the facility since its acquisition by the company last year. Rubicon Research said that during the 12 months following the acquisition, it completed the integration of the facility, implemented its quality management systems, and fulfilled regulatory filing requirements that led to the inspection. At the conclusion of the inspection, the US FDA issued a Form 483 with two observations. The company clarified that the observations are procedural in nature and do not relate to data integrity. It added that it is confident of working closely with the regulator to address the observations and complete the evaluation process in a timely manner. Rubicon Research said a successful outcome of the inspection, achieved a little over a year after acquiring the facility, would reflect its strong quality and compliance culture and reinforce its regulatory track record. The company also reiterated its earlier guidance and stated that it remains confident of ramping up commercial operations at the facility from the first quarter of calendar year 2027. Rubicon Research is a pharmaceutical formulations company focused on innovation-led research and development, with a growing portfolio of specialty products and drug'device combination offerings aimed at regulated markets. Rubicon Research surged 12.55% to Rs 1,130 after the company's consolidated net profit soared 100% to Rs 76.78 crore on a 43.49% increase in revenue from operations to Rs 513.91 crore in Q4 FY26 over Q4 FY25. The counter jumped 4.69% to Rs 1,363.80 on the BSE. Powered by Capital Market - Live

Profit before tax (PBT) jumped 93.26% YoY to Rs 98.68 crore in Q4 FY26. EBITDA stood at Rs 121.3 crore in Q4 FY26, up 67.2% compared with Rs 72.6 crore in Q4 FY25. EBITDA margin expanded to 23.6% in Q4 FY26 as against 20.3% in Q4 FY25. In dollar terms, revenue rose 35% to $56 million in Q4 FY26 from $41 million in Q4 FY25. Approximately 98% of the company's revenue is denominated in US dollars. On full year basis, the company's consolidated net profit jumped 83.63% to Rs 246.73 crore in FY26 compared with Rs 134.36 crore in FY25. Revenue from operations climbed 36.57% to Rs 1,753.95 crore in FY26 from Rs 1,284.27 crore posted in FY25. Meanwhile, the company's board recommended a dividend of Rs 1.50 per equity share of the face value of Re 1 each fully paid up, for the financial year ended March 31, 2026. Rubicon Research is a pharmaceutical formulations company focused on innovation-led research and development, with a growing portfolio of specialty products and drug'device combination offerings aimed at regulated markets.Powered by Capital Market - Live

Rubicon Research announced that the Board of Directors of the Company at its meeting held on 29 May 2026, inter alia, have recommended the final dividend of Rs 1.5 per equity Share (i.e. 150%) , subject to the approval of the shareholders.

Net profit of Rubicon Research rose 111.83% to Rs 76.79 crore in the quarter ended March 2026 as against Rs 36.25 crore during the previous quarter ended March 2025. Sales rose 43.49% to Rs 513.92 crore in the quarter ended March 2026 as against Rs 358.15 crore during the previous quarter ended March 2025. For the full year,net profit rose 83.64% to Rs 246.74 crore in the year ended March 2026 as against Rs 134.36 crore during the previous year ended March 2025. Sales rose 36.57% to Rs 1753.96 crore in the year ended March 2026 as against Rs 1284.27 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales513.92358.15 43 1753.961284.27 37 OPM %23.1020.23 -22.8220.58 - PBDT110.9560.72 83 365.80231.11 58 PBT98.6951.06 93 320.53194.52 65 NP76.7936.25 112 246.74134.36 84 Powered by Capital Market - Live

Rubicon Research will hold a meeting of the Board of Directors of the Company on 29 May 2026.

The deal values Arinna at an enterprise value of Rs 200 crore on a cash and debt-free basis, with the purchase consideration for the stake pegged at around Rs 175.92 crore. The transaction will be executed entirely in cash and is subject to customary closing conditions and regulatory approvals. Incorporated in 2013, Arinna operates a portfolio of over 60 brands across chronic therapies, including antiepileptics, antidepressants, antipsychotics and thymoleptics. The company has an established distribution network covering more than 4,000 prescribers across India through stockists, distributors and retail pharmacies. Arinna reported turnover of Rs 71.5 crore in FY25, Rs 65.14 crore in FY24, and Rs 60.06 crore in FY23, indicating steady growth in its domestic formulations business. Rubicon said the acquisition strengthens its strategy of expanding in chronic therapies, particularly the CNS segment, where it sees long-term growth potential. The company added that Arinna's distribution reach and product portfolio, along with its pipeline of specialty products and drug-device combinations, will support deeper access to patients and prescribers in India. The acquisition is expected to be completed within one month of signing definitive agreements, or within mutually agreed timelines. Commenting on the acquisition, Parag Sancheti, Rubicon's Chief Executive Officer said 'The past decade has demonstrated the effectiveness of Rubicon's playbook of R&D innovation, execution rigor and impeccable compliance standards which enabled us to scale our US revenues by over 32 x from FY15 to FY25 while delivering best-in-class return ratios. Arinna now provides us a launchpad for deploying this playbook in the Indian domestic formulations market. Strategic M&A has always been integral to Rubicon's strategy and our confidence stems from having successfully integrated and scaled acquisitions to foray into new segments such as US branded specialty in 2024 and nasal products development in 2020. I am pleased to welcome Vivek and the Arinna team to the Rubicon family.' Rubicon Research is a pharmaceutical formulations company focused on innovation-led research and development, with a growing portfolio of specialty products and drug'device combination offerings aimed at regulated markets. The company's consolidated net profit climbed 91.2% to Rs 72.79 crore on 51.73% increase in revenue from operations to Rs 475.52 crore in Q3 FY26 over Q3 FY25.